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ABSTRACT 
 
 Four experiments were performed to study the effects of the gonadotropin 
releasing hormone (GnRH) analog, deslorelin acetate (Ovuplant™), on endocrine and 
reproductive characteristics in mares.  The first experiment tested whether anecdotal field 
reports of Ovuplant causing extended interovulatory intervals would be detectable under 
controlled, experimental conditions.  The use of Ovuplant to hasten ovulation in 13 
mares, compared to 12 controls, increased (P < 0.05) the interovulatory interval by 6.2 d 
and suppressed (P < 0.05) plasma concentrations of both luteinizing hormone (LH) and 
follicle stimulating hormone (FSH) for approximately 11 d.  Two mares receiving 
Ovuplant did not return to estrus within 30 d.  In the second experiment, 10 control mares 
and 10 mares induced to ovulate with Ovuplant were administered GnRH (50 µg) on d 1, 
4, 7, and 10 after ovulation.  Again, treated mares had a longer (4.4 d, P < 0.05) 
interovulatory interval and suppressed LH and FSH concentrations in daily plasma 
samples.  The gonadotropin response to GnRH was lower (P < 0.05) in the deslorelin 
mares on d 1, 4, and 7, indicating a lack of pituitary responsiveness.  In the third 
experiment, 9 stallions and 12 steroid-treated geldings were used to determine if males 
were potential models for studying the deslorelin-induced gonadotropin suppression.  In 
both cases, treatment with Ovuplant caused an initial rise in both gonadotropins followed 
by suppression for about 14 d.  In the last experiment, 21 mares were used to determine if 
multiple doses of deslorelin would cause complete ovarian shutdown.  Mares received 
either sham injections, three Ovuplant implants on the first day, or one implant per day 
for 3 d (n = 7/group).  Treatment with multiple deslorelin implants increased (P < 0.05) 
the interovulatory interval by 14.8 d and suppressed LH and FSH concentrations for 
 ix
approximately 25 d, however no mares exhibited complete ovarian shutdown.  In 
conclusion, deslorelin acetate implants in horses in the form of Ovuplant induce short-
term increases in LH and FSH secretion followed by long-term suppression of these 
concentrations and an insensitivity of the pituitary to GnRH.  In a small percentage of 
mares, long-term ovarian shutdown is a possibility.  
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CHAPTER I 
INTRODUCTION 
 The horse industry is concerned with reducing the number of breedings per cycle, 
shortening estrus, and getting mares in foal earlier.  One means of accomplishing these 
goals is shortening the time to ovulation.  The estrous cycle of the mare is extremely long 
in comparison to other domesticated livestock, with a mean of 5 to 7 d in length 
compared with less than 1 d for cows, ewes, and does, and 2 d for sows.  This long estrus 
means numerous breedings per cycle to ensure the mare is mated close to the time of 
ovulation.  Additional breedings per cycle result in more labor, overuse of the stallion, 
and more costs to the mare owner.  If the time of ovulation could be more accurately 
predicted, mare owners could reduce their breeding costs and stallion owners could 
reduce the physical demands on their stallions.   
 Ovuplant™ (Fort Dodge Animal Health, Overland Park, KS), a commercially 
available implant, has been proven to hasten ovulation in estrous mares with a follicle 
greater than 30 mm in diameter.  The active ingredient in Ovuplant is deslorelin acetate.  
Deslorelin is an analog of gonadotropin releasing hormone (GnRH) and shortens the time 
to ovulation by causing increased luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) concentrations, resulting in a hastening of maturation of the ova and a 
fertile ovulation.  The vast majority of mares treated with Ovuplant when they achieve a 
follicle greater than 30 mm will ovulate within 48 h; therefore, a mare can be treated with 
a deslorelin implant on d 1 (the day a follicle >30 mm is detected) and bred on d 2.  The 
mare will most likely ovulate on d 2 or 3 and be going out of estrus by d 3 or 4.  This 
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method of ultrasonography and deslorelin implantation has allowed breeders to reduce 
the number of breedings per cycle to one. 
After the first year of commercial availability of Ovuplant in the United States, 
several reports began circulating that mares not getting pregnant to the Ovuplant-induced 
ovulation had a delayed return to estrus and subsequent ovulation.  Moreover, it appeared 
that in some instances Ovuplant-treated mares went anestrous and were unbreedable for 
the season. 
Based on these anecdotal reports, the series of experiments described herein were 
initiated 1) to determine, under controlled conditions, if there was in fact a suppression of 
cyclicity following an ovulation induced by deslorelin implantation, 2) to study the 
underlying endocrine changes involved in the suppression, and 3) to study possible 
mechanism(s) by which this anovulation occurred. 
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CHAPTER II 
REVIEW OF LITERATURE 
Hypothalamic-Pituitary Axis 
The hypothalamus has been described as the ‘master gland’ (Ginther, 1992) 
because it serves as the collecting center for information and then converts neural signals 
to hormonal signals (Guyton and Hall, 1996).  The hypothalamus produces GnRH, the 
pivotal regulatory hormone of reproduction.  Hypothalamic GnRH is a decapeptide (10 
amino acids) and has a short half-life (5 to 10 min; Conn et al., 1986, 1987).  The 
sequence of the amino acids that make up GnRH is (1) glutamine, (2) histidine, (3) 
tryptophan, (4) serine, (5) tyrosine, (6) glycine, (7) leucine, (8) arginine, (9) proline, and 
(10) glycine.  Synthesis of GnRH in some species occurs in neurons whose cell bodies 
are located in the arcuate nuclei of the hypothalamus (Guyton and Hall, 1996); however 
in the horse, synthesis is evenly distributed throughout the hypothalamus (Strauss et al., 
1979).  GnRH controls reproduction by acting on the adenohypophysis to cause a cascade 
of hormonal events.  The major function of GnRH is to stimulate the secretion of the 
gonadotropins, LH and FSH.  Another function of GnRH is to stimulate the production of 
its own receptor (Clayton, 1989).  In response to appropriate stimuli, GnRH is released in 
a pulsatile manner, enters the hypothalamic-pituitary portal system, and travels to the 
adenohypophysis where it bathes the gonadotropes (Ginther, 1992).  The pulsatile release 
of GnRH leads to pulsatile release of the gonadotropins (Dyer, 1989).  It has been 
suggested that differential release of LH and FSH may be due to the pulse frequency of 
GnRH secretion (Savoy-Moore and Swartz, 1987). 
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 Concentrations of GnRH in peripheral blood, such as in the jugular vein, are too 
low to be detected, making determination of release from the hypothalamus a difficult 
task.  However, a technique involving the cannulation of the intercavernous sinus, into 
which pituitary venous blood flows, has allowed the direct study of GnRH secretion 
(Alexander and Irvine, 1987).  Investigations into the seasonal changes in the 
hypothalamic-hypophyseal axis revealed minimal concentrations of GnRH during 
anestrous.  GnRH concentrations gradually increased during transition to reach maximal 
levels during the breeding season (Hart et al., 1984; Sharp and Grubaugh, 1987).  
Concentrations of LH were low or undetectable during anestrus and progressively 
increased though transition to estrus, while FSH concentrations did not vary (Hart et al., 
1984; Silvia et al., 1986).  Similarly, mares immunized against GnRH had lower 
circulating concentrations of LH and FSH, an absence of estrus behavior, and a reduction 
in follicular activity (Garza et al., 1986; Safir et al., 1987).  Concentrations of LH are low 
during diestrus, begin to increase before estrus, increase progressively during estrus, peak 
the day after ovulation, and decrease to baseline values over the next 4 to 6 d (Ginther, 
1992).  In contrast, concentrations of FSH are low during estrus, increase after ovulation 
and peak during mid-diestrus, and decrease with the advancing diameter of the next 
dominant, pre-ovulatory follicle (Ginther, 1992).  During the periovulatory period, 
secretion of GnRH, LH, and FSH occurs continuously with synchronous pulses 
superimposed on the tonic background (Alexander and Irvine, 1993).  
Treatment with exogenous GnRH causes a rapid increase in secretion of both 
gonadotropins.  A single injection of GnRH to seasonally anovulatory mares, ovulatory 
mares, and stallions caused a transient increase in concentrations of LH (Ginther and 
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Wentworth, 1974).  A single injection of GnRH caused FSH concentrations to increase to 
levels comparable with peak levels seen during the diestrous period (Evans and Irvine, 
1979).  Constant infusion of GnRH resulted in continuing LH release (Garcia and 
Ginther, 1978). 
Treatment with GnRH or its analogs has been the subject of numerous studies into 
controlling the reproductive cycle of the mare.  Synthetic GnRH has been reported to be 
successful at inducing ovulation in mares with inactive or sub-normally active ovaries 
(Heinze and Klug, 1975).  Administration of synthetic GnRH during estrus stimulated the 
release of LH and reduced the duration of estrus (Irvine et al., 1975).  These initial 
reports sparked interest in the potential of using GnRH for induction of the first ovulation 
of the breeding season and in the timing of ovulation in the estrous mare, and numerous 
experiments were subsequently carried out testing these possibilities.  Regimes of native 
GnRH alone (0.4 mg/8 h for 14 d; Bailey and Douglas, 1977) or GnRH with progesterone 
(Evans and Irvine, 1976, 1977) caused ovulation near the end of the anovulatory season.  
Numerous other regimens of repeated or continuous GnRH/GnRH agonists have been 
shown to be successful for causing follicular development and ovulation during the 
anestrous season (summarized in Table 5.5, p. 167 in Ginther, 1992). 
Down-Regulation 
Research with female monkeys was used to show that GnRH secretion is 
“obligatorily intermittent with episodes of secretion separated by periods of 
nonsecretion” (Knobil, 1980).  That is, normal gonadotropin secretion is dependent upon 
pulsatile, or intermittent, secretion of GnRH, as opposed to a continuous secretion.  
Continuous secretion exposes GnRH receptors to continuous stimulation, and an eventual 
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decrease in receptor numbers, which results in refractoriness (Knobil, 1980) that leads to 
a suppression of endogenous gonadotropins.  The lack of gonadotropin inhibits 
reproductive function including follicular development, ovulation, and luteal function 
(Fraser, 1981).  The decrease in receptor numbers on the gonadotropes has been termed 
“down-regulation,” which has been so effective in some species that it has been used as a 
method of contraception (Irvine, 1983).  The possible causes of the reduction in plasma 
LH and FSH concentrations include reduced endogenous GnRH secretion from the 
hypothalamus (Crowder et al., 1986), desensitization of the pituitary to GnRH 
stimulation, and(or) depletion of LH and FSH in the pituitary.  The prolonged 
gonadotropin suppression seen in pituitary down-regulation following constant high 
GnRH stimulation (Heber and Swerdloff, 1981; Nett et al., 1981; Sandow, 1983) is 
generally caused by reduced sensitivity of the gonadotropes to further GnRH stimulation 
(desensitization; Belchetz et al., 1978; Zilberstein et al., 1983). 
Down-regulation in other species has been shown to involve a reduction in the 
number of GnRH receptors plus a perturbation of post-receptor mechanisms (Smith et al., 
1983; Conn et al., 1987).  In research with ewes, Crowder and coworkers (1986) induced 
down-regulation with continuous GnRH infusion and reported no dramatic alteration in 
pituitary LH and FSH concentrations. 
 In general, mares have been thought to be relatively refractory to down-regulation 
by GnRH analogs (Fitzgerald et al., 1993; Irvine and Alexander, 1993).  In horses, 
constant treatment (28 d) with large doses (1.3 mg/kg/day) of a GnRH agonist suppressed 
LH concentrations similar to the suppression reported in other species (Fitzgerald et al., 
1990).  Treatment of horses with high doses (10 mg/d) of a GnRH analog resulted in a 
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reversible suppression of ovarian activity causing a lengthening of the estrous cycle 
(Palmer and Quellier, 1988).  However, additional trials with prolonged continuous 
administration of GnRH suggested that horses are not as sensitive to prolonged treatment 
as other species.  Constant infusion of GnRH (24 h) resulted in a continuous LH release 
in horses (Garcia and Ginther, 1978).   Osmotic minipumps that constantly delivered 
GnRH for 28 d maintained LH secretion (Hyland et al., 1987) and induced prolonged 
gonadotropin secretion without refractoriness (Allen et al., 1987) even at relatively large 
doses (Turner and Irvine, 1992).  Administration of up to 50 mg/d of a potent GnRH 
agonist had no suppressive effect on LH secretion, sexual behavior, or semen 
characteristics of stallions; in mares, luteal phase concentrations of LH were maintained, 
but follicular development was suppressed, although only after 30 d of treatment 
(Montovan et al., 1990).  Compared to ruminants and humans, the horse does in fact 
seem less sensitive to the suppressive effects of continual high levels of GnRH or 
agonists. 
GnRH Analogs 
 Once the structure of hypothalamic GnRH was known, considerable effort was 
put into finding modifications of the hormone that would produce more potent “analogs,” 
or agonists, for use in clinical medicine.  Most GnRH analogs are produced by the 
substitution and(or) removal of one or more amino acids.  Substitution of the glycine at 
position 6 with D-alanine, tryptophan, or serine confers more structural and metabolic 
stability, thereby prolonging the half-life and action of the analog (Monahan et al., 1973; 
Sandow et al., 1978).  Removal of the terminal glycine (position 10) and amidation of the 
proline at position 9 also results in an increase in agonist activity (Sandow et al., 1978).  
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Substitutions near the N terminal, particularly of histidine in position 2, produce 
antagonists, which bind to the GnRH receptor but do not turn on the intracellular 
machinery to increase gonadotropin production and secretion (Sandow et al., 1978). 
Several researchers have shown the utility of human chorionic gonadotropin 
(hCG) for hastening ovulation in the estrous mare (Loy and Hughes, 1966; Sullivan et al., 
1973; Voss et al., 1975).  Unfortunately, hCG is a human hormone, therefore foreign to 
the horse, and acts as an antigen allowing for the development of anti-hCG antibodies 
(Roser et al., 1979).  Repetitive use of hCG has been shown to result in a diminishing 
response (Sullivan et al., 1973).  Due to this problem with hCG, GnRH analogs have 
been tested widely as an alternative for inducing ovulation in the mare.  The benefits of a 
GnRH analog include 1) its smaller molecular weight makes it less antigenic, 2) it may be 
used for alternate cycles with hCG, 3) it is a synthetic product, eliminating the possibility 
of viral contamination, and 4) its supply is not dependent upon pregnant women.   
 Several different GnRH agonists have been studied in the horse.  One of these 
agonists, buserelin, has proven successful for inducing ovulation in estrous mares with a 
follicle >35 mm in diameter; however, twice daily injections were required (Squires et 
al., 1981). 
Deslorelin 
 Deslorelin is a GnRH analog produced by substituting tryptophan for glycine at 
position 6, removing the glycine at position 10, and amidating the proline at position 9 
(6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-Desglycinamide LHRH; Peptide 
Technology Limited, Dee Why, NSW 2099, Australia).  Deslorelin is commercially 
available as Ovuplant, a short-term implant that releases 2.2 mg of deslorelin over 2 to 3 
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d.  Ovuplant is a white cylindrical tablet (2.3 x 3.7 mm).  Ovuplant has been shown to be 
effective in increasing LH concentrations and hastening ovulation in cyclic mares 
(McKinnon et al., 1993; Meinert et al., 1993; Jöchle and Trigg, 1994; Lubbecke et al., 
1994; Squires et al., 1994; Mumford et al., 1995) and in inducing ovulation in transitional 
mares (McKinnon et al., 1997).  Three studies have directly compared Ovuplant to hCG, 
and those studies reported a treatment-to-ovulation interval of 1.98 and 1.88 d 
(McKinnon et al., 1993), 46.9 and 43 h (Meinert et al., 1993), and 2.2 and 2.2 d 
(Vanderwall et al., 2001), respectively.  Donadeu (1997) administered deslorelin implants 
to mares and reported an initial short-term increase in the concentrations of circulating 
gonadotropins.  This increase in the gonadotropins coincided with the release of 
deslorelin from the implant.  Deslorelin concentrations peaked (~400 pg/mL) at 3 to 6 h 
after implantation and declined to near baseline within 24 h.  Mumford et al. (1995) 
treated mares with 3 or 5 times the recommended dose of deslorelin implants over three 
consecutive cycles; they reported an increase in the interovulatory interval for mares 
administered the “5x” dose and noted diminished follicular activity in the “3x” and “5x” 
dose groups.  Some mares in the “5x” group never reached the criteria for the third 
implantation (a follicle >30 mm). 
Rationale for Present Experiments 
Even after the extensive testing of deslorelin in mares for use in hastening 
ovulation, after the first year of commercial availability of Ovuplant in the United States, 
word-of-mouth reports began circulating of problems in mares not becoming pregnant at 
the induced ovulation.  When the present series of experiments was initiated, no 
published reports in the literature existed.  Thus, the first step was to determine, under 
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controlled experimental conditions, whether the alleged problems were reproducible.  
Given the results of the first experiment (Chapter III), subsequent experiments were 
designed to further study the endocrine basis of the prolonged interovulatory interval and 
occasional anestrus produced by Ovuplant administration. 
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CHAPTER III 
PROLONGED INTEROVULATORY INTERVAL AND HORMONAL CHANGES IN 
MARES FOLLOWING THE USE OF A DESLORELIN IMPLANT TO HASTEN 
OVULATION* 
 
 
Introduction 
 
The early induction of ovulation in the mare is a valuable management tool, and 
the various methods towards this end, including injections of HCG, prostaglandin-F2α 
(PGF2α), and GnRH or one of its analogs, have been used with varying degrees of success 
(reviewed by Jöchle and Trigg in 1994).  Ovuplant, a short-term implant containing the 
GnRH analog deslorelin acetate, recently became commercially available in the United 
States for hastening ovulation in mares.  However, in its first year of use, there have been 
anecdotal reports from the field that mares not becoming pregnant after Ovuplant-
induced ovulation often have delayed return to estrus and prolonged interovulatory 
interval, particularly after PGF2α-induced luteal regression commonly used in embryo 
transfer programs.  Similar effects were noted by Mumford et al. (1995) in mares 
administered 3 or 5 times the recommended dose of deslorelin implants over three 
consecutive cycles not altered by PGF2α administration.  Thus, the present experiment 
was designed 1) to determine if the field observations were repeatable under controlled 
experimental conditions and 2) to gather endocrine data that might yield information on 
the underlying cause(s) of this delayed return to estrus. 
Materials and Methods 
Twenty-five, non-lactating light horse mares were used.  The mares were between 
3 and 20 yr of age, were of good body condition (6 to 8; Henneke et al., 1983), and were 
                                                 
* Reprinted by permission of Journal of Equine Veterinary Science 
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known to have cycled normally the previous year.  They were kept on native grass 
pasture and supplemented with grass hay as needed to maintain body condition.  The 
experiment was performed in the months of April through July; the transition period in 
Louisiana normally starts around late February or early March. 
Beginning in April, mares were checked each morning for behavioral estrus with 
a vigorous stallion.  Once a mare came into estrus, her ovaries were examined daily via 
transrectal ultrasonography, and the diameter of all detectable follicles recorded.  Based 
on these follicle counts, mares were generally classified as having either high or low 
follicle numbers, and their allotment to treatment took this into consideration such that 
high and low follicle numbers were evenly distributed between groups.  The first day a 
mare achieved a follicle greater than 30 mm, she received either a single implant of 
Ovuplant (treated mares) in the neck region or was administered a sham injection (same 
size needle).  Assignment to the treatment and control groups was random for the first 
mare and then alternated except when follicular number dictated; no more than three 
mares of either category were assigned consecutively to the treatment or control groups.  
Additionally, treatments were coded such that the assignments of individual mares were 
unknown to the personnel involved with data collection. 
The ovaries of each mare were examined daily during the first estrus until 
ovulation was detected, after which each mare was examined on an every other day 
schedule.  On d 7 after ovulation, each mare was administered PGF2α (LutalyseTM, 
Upjohn, Kalamazoo, MI) to induce regression of the corpus luteum. Every other day 
examinations were continued until a mare returned to estrus or developed a follicle 30 
 13
mm or greater, at which time the mare was switched to daily examinations until ovulation 
was detected on this second estrus. 
Samples of jugular blood were drawn each morning beginning on the first day of 
the first estrus and ending 3 d after ovulation on the second estrus.  All blood samples 
were collected prior to estrus detection (except for the very first day) and prior to 
ultrasound examination.  Heparinized plasma was harvested by centrifugation and was 
stored frozen.  Plasma samples were analyzed for LH (Thompson et al., 1983a), FSH 
(Thompson et al., 1983c), progesterone (Diagnostic Systems Laboratory, Webster, TX), 
and estradiol (Diagnostic Systems Laboratory) by radioimmunoassay. 
Two of the mares receiving Ovuplant had interovulatory intervals greater than 30 
d after treatment.  For statistical analyses, the data for these mares were excluded from 
the treated group.  One control mare had incomplete luteal regression after PGF2α 
administration on d 7, thus her data were not included with those of the control group.  
Data for single point variables (such as length of the interovulatory interval) were 
analyzed by one-way analysis of variance (Steel and Torrie, 1980) with PC-SAS (SAS 
Institute, Cary, NC).  Data for variables from repetitive sampling (e.g., hormonal 
concentrations over time) were analyzed by ANOVA in a split-plot design (Gill and Hafs, 
1971).  Differences between groups in the treatment x time interactions from these latter 
analyses were assessed by the LSD-test (Steel and Torrie, 1980). 
Results 
For the 22 mares in the analysis, mean diameter of the largest follicle on the day 
of treatment or sham injection at the first estrus did not differ (P = 0.713) between groups  
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(Table 3.1).  After treatment, the mean diameter of the pre-ovulatory follicle at the exam 
prior to ovulation was smaller (P = 0.037) for mares receiving Ovuplant than for control 
mares.  Although there was no difference between groups for the mean interval from 
treatment or sham injection to ovulation on the treatment estrus (P = 0.438), the general 
trend was in the direction for shorter intervals in the treated group. When analyzed as 
percentage of mares ovulating within a specified interval after treatment, there were more 
mares ovulating within 48 (P = 0.095) and 72 (P = 0.059) h after Ovuplant administration 
than after sham injection.  The interval between the first ovulation on the treatment estrus 
and that on the subsequent estrus (interovulatory interval) was greater (P = 0.0001) for 
mares administered Ovuplant compared to controls (Table 3.1). 
Hormonal data were expressed relative to the day of ovulation (d 0) on the first 
estrus.  Plasma concentrations of LH (Figure 3.1a) were greater (P < 0.05) in control 
mares than in mares receiving Ovuplant on the day of ovulation and for the next 4 
consecutive days.  They were again greater (P < 0.05) on d 9, 11, 19, and 20 after the first 
ovulation.  Plasma concentrations of FSH (Figure 3.1b) were higher (P < 0.05) in mares 
receiving Ovuplant relative to controls on the day preceding the first ovulation.  Within 4 
d after ovulation, plasma FSH concentrations began to rise in control mares but actually  
dropped slightly in mares receiving Ovuplant, resulting in lower (P < 0.05) average 
concentrations relative to controls from d 4 through 11 after the first ovulation.   
Plasma progesterone concentrations increased in both groups of mares after the first 
ovulation (Figure 3.2a), but were lower (P < 0.05) in mares receiving Ovuplant than 
in control mares on d 5 and 6.  Average concentrations dropped precipitously 1 d after 
PGF2α administration on d 7, and average concentrations were again lower (P < 0.05) in 
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Figure 3.1 Plasma concentrations of LH (a) and FSH (b) in mares administered sham 
injections (control) or treated with a deslorelin implants (deslorelin) on the first estrus.  Data 
are expressed relative to the day of ovulation on the first estrus (d 0) for both groups.  
Prostaglandin injection was administered to all mares on d 7.  Asterisks indicate differences 
(P <  0.05) between groups on specific days.  The pooled SEM from the analyses of variance 
were 0.7 and 1.2 ng/ml for LH and FSH, respectively.
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Figure 3.2 Plasma concentrations of progesterone (a) and estradiol (b) in mares administered 
sham injections (control) or treated with a deslorelin implants (deslorelin) on the first estrus.  
Data are expressed relative to the day of ovulation on the first estrus (d 0) for both groups.  
Prostaglandin injection was administered to all mares on d 7.  Asterisks indicate differences (P 
< 0.05) between groups on specific days.  The pooled SEM from the analyses of variance were 
1.4 ng/ml and 1.2 pg/ml for progesterone and estradiol, respectively.
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Table 3.1.  Mean follicular diameter and ovulation data for mares administered sham 
injections (control) or treated with deslorelin on the first estrus. 
 
Item Control Deslorelin SEM P-value 
Number of mares 11 11   
Follicle diameter at treatment, mm 36.2 35.5 1.21 0.713 
Follicle diameter  before ovulation, 
mm 
42.4 37.9 1.33 0.037 
Treatment to ovulation, d 3.4 2.8 0.49 0.438 
Number ovulating within 48 h (%) 3/11 (27.3%) 7/11 (63.6%)  0.095 
Number ovulating within 72 h (%) 6/11 (54.5%) 10/11 (90.9%)  0.059 
Interovulatory interval, d 15.8 22.0 0.60 0.0001 
 
mares receiving Ovuplant than in control mares on d 8, 17, 18, and 19.  Plasma estradiol 
concentrations (Figure 3.2b) were higher (P < 0.05) in control mares than in mares  
receiving Ovuplant on the day of the first ovulation and for the preceding 2 d and again 
on d 11 through 17. 
Follicular data were compared relative to the following reference points:  the day 
of treatment, the day of the first ovulation, the day of PGF2α administration, and the day 
of ovulation on the estrus following PGF2α administration (second estrus and ovulation).  
Diameter of the largest follicle (Figure 3.3a) was greater in control mares than in mares 
receiving Ovuplant 1 d before the first ovulation was detected (as indicated in Table 3.1), 
but did not differ between groups otherwise.  Numbers of other large (25 mm and larger; 
Figure 3.3b) follicles were greater (P < 0.05) in control mares relative to mares receiving 
Ovuplant 1 d before ovulation on the second estrus.  Relative to mares receiving 
Ovuplant, total number of medium (11 to 24 mm) follicles (Figure 3.4a) were lower (P < 
0.05) in control mares on the day of the first ovulation, but were then higher (P < 0.05) on 
the day of the second ovulation and d 4 and 3 preceding it.  Total number of small (10  
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Figure 3.3 Diameter of the largest follicle (a) and total number of other large (25 mm and larger) 
follicles (b) on the ovaries of mares administered sham injections (control) or treated with a 
deslorelin implant (deslorelin) on the first estrus.  Data are expressed relative to the day of 
treatment (trt), the day of ovulation on the treatment estrus (ov-1), the day of Prostaglandin 
administration (PG), and the day of ovulation on the second estrus (ov-2).  Asterisks indicate 
differences (P < 0.05) between groups on specific days.
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Figure 3.4 Total number of medium (11-24 mm) (a) and small (10 mm and smaller) 
(b) follicles on the ovaries of mares administered sham injections (control) or treated 
with a deslorelin implant (deslorelin) on the first estrus.  Data are expressed relative 
to the day of treatment (trt), the day of ovulation on the treatment estrus (ov-1), the 
day of Prostaglandin administration (PG), and the day of ovulation on the second 
estrus (ov-2).  Asterisks indicate differences (P < 0.05) between groups on specific 
days.
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mm and smaller) follicles (Figure 3.4b) differed (P < 0.05) between groups only on d 2 
preceding the second ovulation, when they were highest in control mares. 
Of the two mares receiving Ovuplant that did not return to estrus within 30 d, one 
mare (#386, Figure 3.5) ovulated 48 h after treatment, had a normal appearing 
progesterone rise thereafter, and responded to PGF2α with a rapid decline in progesterone 
concentrations.  Her ovaries then became inactive, gaining no greater than a 10-mm 
follicle through 56 d after treatment, and estradiol and progesterone concentrations 
confirmed this inactivity.  Concentrations of LH and FSH gradually increased through d 
30 to 40 and plateaued at elevated levels, indicative of a total lack of negative feedback 
from the ovaries (i.e., similar to an ovariectomized mare).  This mare remained inactive 
through her last exam, which was several months after treatment. 
The other treated mare that did not return to estrus within 30 d (#376, Figure 3.6) 
had a similar pattern in follicular activity and LH and FSH concentrations for 30 d, but 
eventually developed a 35-mm follicle and ovulated on d 31 after treatment.  Moreover, 
she never had a rise in progesterone concentrations after her apparent first ovulation, 
which was 72 h after treatment. 
Discussion 
Deslorelin acetate, the active ingredient of the Ovuplant implant, has proven to be 
an effective alternative to hCG for inducing ovulation in mares with pre-ovulatory 
follicles of 30 mm or larger (McKinnon et al., 1993; Meinert et al., 1993; Jöchle and 
Trigg, 1994; Squires et al., 1994; Ganheim et al., 1995; Mumford et al., 1995; Meyers et 
al., 1997), and was tested extensively in field trials in North and South America, Europe 
and Australia (Jöchle and Trigg, 1994).  The first anecdotal reports of mares not returning  
Figure 3.5 Plasma concentrations of LH, FSH, and progesterone in mare #386 after treatment with 
a deslorelin implant 2 days before ovulation (d 0).  Estrus is designated, treatment is designated 
by T, and prostaglandin injection is designated by PG.  Diameter of the largest follicle (mm) on 
either ovary is indicated by the solid diamonds.  After an apparent normal ovulation, progesterone 
concentrations increased as expected, and subsequently decreased after injection of PG.  
Thereafter, little follicular activity was noted, and concentrations of LH and FSH increased to 
gonadectomized-like levels, indicating a lack of feedback from the ovaries.  This condition 
persisted throughout the breeding season and was still present at the last examination in October.
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Figure 3.6 Plasma concentrations of LH, FSH, and progesterone in mare #376 after treatment with 
a deslorelin implant 2 d before ovulation (d 0).  Estrus is designated, treatment is indicated by T 
and prostaglandin injection is indicated by PG.  Diameter of the largest follicle (mm) on either 
ovary is indicated by the solid diamonds.  After what appeared to be an ovulation (based on the 
morphological changes in a 38 mm follicle present on the left ovary), progesterone concentrations 
never increased and follicular activity decreased for approximately 23 days.  Concentrations of 
LH and FSH increased to gonadectomized-like levels, and in this case the ovary responded with a 
pre-ovulatory follicle, a decrease in FSH concentrations, and ovulation on d 31.  Progesterone 
concentrations increased thereafter in an apparent normal manner and LH concentrations began to 
decrease accordingly.
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to estrus at the expected time began to circulate in the spring of 1999 when Ovuplant 
became commercially available in the United States.  Allegedly, the degree to which  
mares were delayed in their return to estrus varied from slight to extensive, and those not 
returning for extensive periods were often associated with PGF2α-induced short-cycling 
commonly used in embryo collection programs.  Due to the potentially tenuous nature of 
such observations in the field, the present experiment was designed to gather information 
under experimentally controlled conditions on the occurrence and possible underlying 
cause(s) of this phenomenon. 
Under the conditions of this experiment, the use of Ovuplant resulted in an 
interovulatory interval 6.2 d longer than that in control mares, not considering the two 
mares that had intervals of greater than 30 d.  Those two mares were not included in the 
data analyses because their responses were so drastically different from the rest.  Whether 
their responses were truly due to Ovuplant is difficult to confirm, and future studies with 
larger numbers of mares are needed to answer the question appropriately.  However, the 
previous field observations did indicate the occurrence of long-term anestrus in a 
percentage of mares, and it is possible that these mares are indicative of that population.  
Moreover, Mumford et al. (1995) described several mares administered 3 or 5 implants of 
deslorelin that had extended interovulatory intervals, lack of follicular growth, and(or) 
total ovarian inactivity.  Thus, it is possible that some mares are exceptionally sensitive to 
the GnRH analog and shut down in response to a single implant. 
The alterations in plasma concentrations of LH and FSH in mares receiving 
Ovuplant likely led to the subsequent alterations in follicular growth.  There was a short-
lived increase in both hormones after insertion of the implant, but thereafter they 
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decreased gradually, indicative of suppression of secretion.  Mumford et al. (1995) 
presented very similar LH and FSH patterns in response to 1, 3 or 5 implants of 
deslorelin, although they indicated that only the highest doses were suppressive.  Given 
that the progesterone patterns after ovulation were similar for the two groups in this 
experiment up through d 6, the lower LH concentrations in the mares receiving Ovuplant 
on d 0 through 4 likely indicate some type of suppression other than progesterone.  
Moreover, FSH concentrations, which increased after ovulation as expected in control 
mares due to the release from feedback by follicular estradiol and inhibin, appeared to be 
suppressed for at least 8 d after ovulation in mares receiving Ovuplant.  In general, mares 
are thought to be relatively refractory to down-regulation by GnRH analogs (Fitzgerald et 
al., 1993); however, these data are reminiscent of such an effect. 
The major result of this suppression of LH and FSH after ovulation seemed to be 
the reduction in medium-sized follicles after PGF2α-induced luteal regression.  Because 
the PGF2α injection was given to mares in both groups on d 7 after ovulation, the 
increased interovulatory interval in mares receiving Ovuplant was due to a delay in 
growth and emergence of a dominant pre-ovulatory follicle after this induced luteal 
regression.  Once that follicle emerged, its diameter up to and at ovulation did not differ 
between groups, as indicated by the data in Figure 3.3a. Similarly, Mumford et al. (1995) 
made a subjective observation that mares administered 3 or 5 deslorelin implants had 
diminished follicular activity for 6 to 10 d after ovulation in non-PGF2α shortened estrous 
cycles, and speculated that this might be due to suppressed follicular development or 
delayed recruitment of dominant follicles. 
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Given the results of the present experiment and those of Mumford et al. (1995) 
and Fitzgerald et al. (1993), it is concluded that the administration of Ovuplant at the 
recommended dosage does indeed alter the interovulatory interval of mares short-cycled 
with PGF2α, and likely is responsible for a small percentage of mares becoming anestrus 
and anovulatory for extended periods of time.  These latter mares are of particular 
concern, because they might be unbreedable for the entire breeding season.  The 
mechanism by which long-term suppression of follicular activity in the face of elevated 
LH and FSH concentrations (indicative of a problem at the ovarian level), seen in the one 
mare in this experiment, needs to be studied further, because understanding that 
phenomenon may provide insight into the cause of other forms of ovarian lesions 
resulting in infertility. 
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CHAPTER IV 
PITUITARY RESPONSIVENESS TO GNRH IN MARES FOLLOWING 
DESLORELIN ACETATE IMPLANTATION TO HASTEN OVULATION* 
 
 
Introduction 
Previous investigation (Johnson et al., 2000) into field reports of prolonged 
interovulatory intervals in mares following use of a commercially available implant of 
deslorelin acetate (Ovuplant) to hasten ovulation revealed that treated mares not only had 
a greater interovulatory interval but also had greatly reduced plasma LH and FSH 
concentrations for approximately 10 d after ovulation.  Although the mares in that 
experiment (Johnson et al., 2000) were short-cycled with PGF2α, similar effects were 
noted for estrous cycles not altered by PGF2α administration by Mumford et al. (1995) in 
mares administered 3 or 5 times the recommended dose of deslorelin implants and by 
Farquhar et al. (2001) and Vanderwall et al. (2001) for mares administered a single 
implant. 
 The prolonged suppression of gonadotropin secretion after ovulation in 
deslorelin-treated mares was characteristic of pituitary down-regulation induced by 
constant high GnRH input (Heber and Swerdloff, 1981; Nett et al., 1981; Sandow, 1983), 
generally characterized by a reduced sensitivity of pituitary gonadotropes to further 
GnRH stimulation (desensitization; Belchetz et al., 1978; Zilberstein et al., 1983).  The 
results of Farquhar et al. (2001), who reported a reduced gonadotropin response to GnRH 
at 10 d after ovulation in deslorelin-treated mares, are consistent with the concept of 
down-regulation.  Alternatively, the observed reduction in gonadotropin secretion may  
                                                 
* Reprinted by permission of Journal of Animal Science 
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have been due to reduced endogenous GnRH input to the pituitary in treated mares 
(Crowder et al., 1986).  The objective of the present experiment was to characterize the 
pituitary responsiveness to exogenous GnRH in the first 10 d after ovulation following 
deslorelin acetate implantation at the normal dosage for hastening ovulation in mares. 
Materials and Methods 
Twelve nonlactating, light horse mares between 4 and 16 yr of age were used 
beginning in April.  All mares were in good body condition (6 to 8, Henneke et al., 1983) 
and were maintained on a combination of rye grass (winter) and native grass pastures.  
Mares were determined to be through the vernal transition period and cycling normally 
before use.  All mares were checked daily with a vigorous stallion throughout the 
experiment for signs of behavioral estrus.  In addition, the ovaries of each mare were 
examined via transrectal ultrasonography three times weekly (Monday, Wednesday, and 
Friday) until detection of a follicle at least 25 mm in diameter or until the mare showed 
signs of estrus, at which time daily examinations were initiated as well as daily blood 
sampling via jugular venipuncture.  Once a follicle > 30 mm was detected for a given 
mare, she was administered either a single Ovuplant implant (n = 6) s. c. in the neck 
region or a sham injection (same needle size, no implant; n = 6) given in the same 
manner.  Assignment to treatment group and administration of treatment were unknown 
to the personnel involved with on-farm data collection.  After treatment, mares were 
followed with daily ultrasound exams until ovulation. 
 On d 1, 4, 7, and 10 following this first ovulation, each mare was challenged i.v. 
with 50 µg GnRH (Sigma), 7-mL blood samples were collected via an indwelling jugular 
catheter at -10, 0, 10, 20, 30, 45, 60, 90, and 120 min relative to GnRH injection.  The 
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dose of GnRH (50 µg) was determined in preliminary trials to be the smallest amount that 
consistently caused a measurable response in both LH and FSH concentrations.  
Ultrasound examinations were also performed on the day of each GnRH challenge, after 
all blood samples had been collected, to determine follicular activity.  Daily ultrasound 
exams were resumed once a mare subsequently returned to estrus and were continued 
though the second ovulation.  Daily blood sampling was continued for 4 d after the 
second ovulation to confirm ovulation via progesterone concentrations.  
 All blood samples in the experiment were placed on ice until centrifugation at 
1,200 x g for 15 min at 5°C.  Plasma was harvested and stored at -15°C until assayed via 
radioimmunoassay for LH (Thompson et al., 1983a), FSH (Thompson et al., 1983c), and 
progesterone (Diagnostic Systems Laboratory).  Intra- and interassay coefficients of 
variation and assay sensitivities were 6%, 9%, and 0.2 ng/mL for LH; 7%, 11%, and 1.4 
ng/mL for FSH; and 5%, 8%, and 0.05 ng/mL for progesterone. 
 Data were analyzed via the GLM procedure of SAS (SAS Inst. Inc.).  Data from 
repetitive sampling over time (daily samples) were analyzed in a split-plot ANOVA (Gill 
and Hafs, 1971) for a completely randomized design (Steel and Torrie, 1980).  The main 
effect of treatment was tested with the mare within treatments term; the time factor and 
its interaction with treatment were tested with the residual error term.  For data from the 
repeated GnRH challenges, a second split was included (day of challenge), and the data 
were analyzed as a split-split-plot design (Steel and Torrie, 1980) with all appropriate 
interactions.  Differences between treatment groups in the treatment x day x minute 
interaction were assessed by the LSD-test (Steel and Torrie, 1980).  Net areas under the 
GnRH-response curves for LH and FSH were calculated by summing the time x 
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concentration increments after subtracting the pre-GnRH average for each mare in each 
challenge; areas were analyzed separately for each day by one-way ANOVA (Steel and 
Torrie, 1980) due to heterogeneity of variances among the four challenge days. 
Results 
The diameter of the largest ovarian follicle on the day of treatment (P = 0.89) and 
the day before ovulation (P = 0.36) did not differ between groups (Table 4.1).  Mares 
receiving a deslorelin implant ovulated an average of 2.0 d earlier (P = 0.0003) and had 
an interovulatory interval 4.4 d longer (P = 0.0361) than control mares (Table 4.1).  After 
the first ovulation, the diameter of the largest follicle present on the GnRH challenge day 
was larger in deslorelin-treated mares on d 1 (P = 0.0067), but smaller (P = 0.021) on d 
10 (Table 4.1) relative to controls.  
 Plasma LH concentrations from daily blood samples in control mares followed 
the expected rise and fall around ovulation and into diestrus (Figure 4.1a).  In mares 
receiving deslorelin, LH concentrations were lower (P < 0.05) relative to those in control 
mares from d 0 to 5, d 7, and again on d 20 to 24 (Figure 4.1a).  Daily plasma 
concentrations of FSH in control mares were low during estrus and followed the expected 
rise after ovulation (Figure 4.1b).  Plasma FSH concentrations in deslorelin-treated mares 
were lower (P < 0.05) relative to controls on d 3 to 13 (Figure 4.1b).  Plasma 
progesterone concentrations were not altered (P = 0.99) by deslorelin treatment (Figure 
4.1c). 
 There were interactions (P < 0.001) among treatments, days, and minutes of blood 
sampling in the ANOVA for both LH and FSH concentrations in the four GnRH 
challenges.  Relative to control mares, the LH (Figure 4.2) and FSH (Figure 4.3)  
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Figure 4.1 Plasma concentrations of LH (a), FSH (b), and progesterone (c) in mares 
administered a deslorelin implant or sham injection (control) during the first estrus.  Data are 
expressed relative to the d of the first ovulation (d 0).  Asterisks indicate differences (P < 0.05) 
between groups on specific days.  The pooled SEM from the analyses of variance were 0.94, 2., 
and 3.6 ng/ml for LH, FSH and progesterone concentrations, respectively.
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Figure 4.2 Plasma LH concentrations for GnRH challenges on d 1, 4, 7, and 10 following 
ovulation for mares administered a deslorelin implant or sham injection (control).  There was a 
treatment x day x minute interaction (P < 0.001) in the analyses of variance.  The vertical line 
indicates the P < 0.05 value.  The pooled SEM was 0.32 ng/ml.
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Figure 4.3 Plasma FSH concentrations for GnRH challenges on d 1, 4, 7, and 10 following 
ovulation for mares administered a deslorelin implant or sham injection (control).  There was a 
treatment x day x minute interaction (P < 0.001) in the analyses of variance.  The vertical line 
indicates the P < 0.05 value.  The pooled SEM was 2.8 ng/ml.
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Table 4.1.  Intervals from treatment to ovulation, between first and second ovulation, and 
diameter of the largest follicle 
 
 
responses to exogenous GnRH were suppressed in the deslorelin-treated mares on d 1, 4, 
and 7.  In agreement, net areas under the curve for the LH (P < 0.008) and FSH (P < 
0.009) responses to GnRH were lower in deslorelin-treated mares on d 1 and 4, and on d 
7 for LH (Figure 4.4). 
Discussion 
Deslorelin acetate, as the commercially available implant, Ovuplant, has been 
proven many times to be effective at hastening ovulation in mares with pre-ovulatory 
follicles larger than 30 mm (McKinnon et al., 1993; Meinert et al., 1993; Jöchle and 
Trigg, 1994).  Shortly after its commercial release in the United States, there were field 
reports that some treated mares displayed either prolonged interovulatory intervals or 
complete anestrus.  The report of Johnson et al. (2000) confirmed, under controlled 
conditions, the deslorelin effect on interovulatory interval for mares short-cycled on d 7 
with PGF2α and extended the observations to include the reduction in LH and FSH 
concentrations following treatment.  Similar results were reported by Farquhar et al. 
(2001) for mares not short-cycled with PGF2α, except that those authors found no  
Item Control Deslorelin SEM P-value 
Treatment to ovulation, d 4.0 2.0 0.26 0.0003 
Interovulatory interval, d 21.0 25.4 1.2 0.036 
Diameter of the largest follicle, mm:     
     Day of treatment 34.0 33.8 0.8 0.892 
     Day 1 before ovulation 41.5 40.0 1.1 0.36 
     Day of ovulation 17.7 20.7 2.2 0.356 
     Day 1 after ovulation 15.3 22.3 1.5 0.007 
     Day 4 after ovulation 19.7 15.3 3.1 0.339 
     Day 7 after ovulation 15.0 16.2 1.5 0.605 
     Day 10 after ovulation 19.2 13.0 1.6 0.021 
Figure 4.4 Area under the curve for LH (a) and FSH (b) responses to GnRH challenges performed 
on d 1, 4, 7, and 10 following ovulation for mares administered a deslorelin implant or sham 
injection (control).  Each day was analyzed separately due to heterogeneity of variances; P-values 
for the differences between groups are shown.  The pooled SEM were 0.69, 1.5, 0.81, and 0.31 
ng/ml-1/h-1 for LH and 3.3, 12.4, 7.3, and 9.5 ng/ml-1/h-1 for FSH for d 1, 4, 7, and 10, 
respectively.
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significant suppression of daily LH concentrations.  Other researchers have reported 
similar extensions in the interovulatory interval of mares treated with deslorelin as 
compared with those receiving no ovulation induction drug and to those induced to 
ovulate with hCG (Morehead et al., 2000; Vanderwall et al., 2001). 
 The effects of deslorelin implantation on time to ovulation, interovulatory 
interval, and plasma concentrations of LH and FSH observed in the present experiment 
were virtually identical to previous results (Johnson et al., 2000).  Because the mares in 
that experiment had been short-cycled with PGF2α injection on d 7 after ovulation, it 
could not be determined whether the shortened diestrous period affected the results.  It is 
now apparent that the normal, recommended dose of deslorelin has profound effects on 
gonadotropin secretion in mares not administered PGF2α as well. 
 For both gonadotropins, there was an initial stimulation of plasma concentrations 
in response to deslorelin implantation.  Although only daily blood samples were collected 
in the present experiment, the short-term release of LH and FSH after deslorelin 
implantation has been characterized (Donadeu, 1997; Johnson et al., 2001), with peaks 
occurring at 6 to 8 h after administration.  This initial rise in both gonadotropins 
corresponds with the release of deslorelin:  peak concentrations of deslorelin (about 400 
pg/mL) occur at 3 to 6 h after implantation and decline to near baseline within 24 h 
(Donadeu, 1997).  As in the present and previous (Johnson et al., 2000) experiments, 
concentrations of both gonadotropins decreased continuously for several days after the 
initial peak. 
 The diameter of the largest follicle on the ovaries did not differ between treatment 
groups on the day of treatment or 1 d before ovulation; however, the interval from 
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treatment to ovulation was shortened by 2 d.  These data are consistent with previous 
studies with deslorelin implants (Jöchle and Trigg, 1994; Mumford et al., 1995).  The 
diameter of the largest follicle was greater in the deslorelin-treated mares on d 1 
following ovulation.  This may have been due to incomplete suppression from the 
dominant follicle ovulating earlier or to the initial temporary rise in LH and FSH 
following implant administration.  By d 10, the diameter of the largest follicle on the 
ovaries of the deslorelin-treated mares was smaller than on the ovaries of the control 
mares, which was likely due to the long-term gonadotropin suppression. 
 The possible causes of the reduction in plasma LH and FSH concentrations 
include 1) a reduction in endogenous GnRH secretion from the hypothalamus, 2) a 
desensitization of the pituitary that usually accompanies down-regulation, and 3) a 
depletion of LH and FSH in the pituitary gland itself.  Previous research with continuous 
infusion of GnRH and the subsequent phenomenon of down-regulation in ewes indicated 
that pituitary LH and FSH contents were not dramatically altered (Crowder et al., 1986).  
The desensitization that occurred in those experiments was the major factor altering 
gonadotropin secretion, although a reduction in endogenous GnRH input was also 
concluded (Crowder et al., 1986).  To differentiate between these two possibilities, the 
present experiment was performed. 
 Both the pre-GnRH concentrations of LH and the LH response to GnRH in 
control mares were characteristic of the stage of the estrous cycle (Alexander and Irvine, 
1986; Ginther, 1992).  Immediately after ovulation (d 1), plasma LH concentrations were 
at their peak, and the response to GnRH was minimal due to the high rate of secretion 
already occurring.  With the drop in LH secretion as progesterone concentrations 
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increased, the LH response to GnRH increased, and maximal response occurred on d 4.  
Later, as the inhibitory effects of progesterone become greater, the LH response to GnRH 
diminished, and was very low by d 10.  The elevated LH concentrations seen in control 
mares on d 20 to 24 coincided with their impending second ovulation, which was delayed 
in the deslorelin-treated mares. 
 Similar to LH, the pre-GnRH concentrations of FSH and the FSH response to 
GnRH in control mares were characteristic of the stage of the estrous cycle.  Plasma FSH 
concentrations were low on d 1, due to residual effects of estradiol and inhibin from the 
dominant follicle (Ginther, 1992).  On d 4 and 7, FSH had been freed of those inhibitory 
effects, and the response to GnRH was characteristic of diestrus.  By d 10, the response 
had begun to diminish, likely due to the onset of the next follicular phase. 
 For mares receiving a deslorelin implant, there was virtually no LH or FSH 
response to the GnRH injections on d 1, 4, and 7 after ovulation.  These results indicate 
that the pituitary glands of these mares were indeed relatively insensitive to the injected 
GnRH, which would support the concept of down- regulation as described in other 
species.  The small dose of GnRH used for the challenges was chosen to approximate the 
endogenous (physiologic) amount of GnRH normally reaching the pituitary gland, as 
opposed to a saturating dose.  In addition, it was felt that each challenge should be kept to 
a minimum to avoid carry-over effects from injection to injection (such that the 
challenges might become similar to replacement therapy for a quiescent hypothalamus).  
Although Alexander and Irvine (1986) calculated even smaller doses as physiologic, 
similar methods used in the present experiment determined 50 µg/mare to be the smallest 
dose that would give consistent responses for both LH and FSH. 
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 Although down-regulation is a common complication in using GnRH and its 
analogs in other species, the horse was thought to be less susceptible to down-regulation 
(Irvine and Alexander, 1993).  That is, horses continually infused with GnRH for 24 h 
had a steady increase in LH concentrations (Garcia and Ginther, 1975).  Osmotic 
minipumps designed to deliver GnRH to horses constantly for 28 d maintained LH 
secretion (Hyland et al., 1987).  Allen et al. (1987) administered long-term (28 d) GnRH 
agonist implants to horses and reported a prolonged gonadotropin secretion without 
refractoriness; Turner and Irvine (1992) reported similar results using higher doses.  
Daily administration of high levels of a GnRH agonist did not suppress LH levels in 
stallions, and luteal levels of LH were maintained in mares; however, follicular activity 
was diminished after 30 d of treatment (Montovan et al., 1990). 
 By d 10 after ovulation, the LH and FSH responses to GnRH were similar for the 
two groups of mares, indicating that the deslorelin effects were waning.  Because the 
onset of the next estrus in the control mares thereafter began confounding the resting 
levels of LH and FSH and their responses to GnRH, subsequent GnRH challenges would 
not have been informative.  One model that might be useful for determining the actual 
length of the deslorelin effect and the characteristics of recovery would be similar 
experiments in stallions or steroid-treated geldings (Johnson et al., 2001), which exhibit 
the same long-term inhibition of LH and FSH secretion. 
 Other than the hastening of the first ovulation (Jöchle and Trigg, 1994; Mumford 
et al., 1995) and few days delay in ovulation on the estrus subsequent to deslorelin 
administration, no other effects on the estrous cycle were observed.  Given the major 
perturbation in plasma LH and FSH concentrations, one might expect a greater effect on 
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follicular populations and onset of the next estrus.  The lack of effect on plasma 
progesterone concentrations after the first ovulation indicates that the formation and 
subsequent function of the corpus luteum are not dependent upon the normally high LH 
concentrations from the day of ovulation onward.  Similar results have been reported for 
mares treated with testosterone propionate during mid-estrus (Thompson et al., 1983b) 
and the subsequent diestrus, in which LH concentrations during estrus were reduced by 
about 50%, whereas, the timing of ovulation and the function of the subsequent corpus 
luteum were unaffected. 
 In conclusion, the reductions in plasma LH and FSH concentrations following 
Ovuplant administration to mares are accompanied by an insensitivity to exogenous 
GnRH challenge for up to 7 d.  Such desensitization is characteristic of the down-
regulation phenomenon, which in other species has been shown to involve a reduction in 
GnRH receptor numbers and a perturbation of post-receptor mechanisms (Smith et al., 
1983; Conn et al., 1987).  Whether endogenous GnRH secretion is altered in these mares, 
as has been suggested for ewes (Crowder et al., 1986), and whether pituitary LH and FSH 
content is reduced, needs to be determined in future experiments. 
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CHAPTER V 
 
EFFECTS OF DESLORELIN ACETATE IMPLANTATION ON LH AND FSH 
CONCENTRATIONS IN STALLIONS AND STEROID-TREATED GELDINGS 
 
 
Introduction 
 The use of commercially available deslorelin acetate implants (Ovuplant) to 
hasten ovulation in mares is associated with an extended interovulatory interval and 
suppression of LH and FSH secretion for approximately 10 d after ovulation (Johnson et 
al., 2000) and an insensitivity of the pituitary to exogenous GnRH challenge (Johnson et 
al., 2002).  Given that many of the LH and FSH responses to steroidal feedback in 
gonadectomized horses are similar for both sexes (Thompson et al., 1979, 1991; Reville-
Moroz et al., 1984), male horses may provide a useful model for studying the suppressive 
effects of deslorelin implantation observed in mares.  Thus, the two experiments 
described herein were designed to determine the effects of deslorelin implantation on LH 
and FSH secretion in stallions and in geldings administered progesterone and estradiol to 
mimic the normal estrous cycle changes in mares. 
Materials and Methods 
 Experiment 1.  Nine light horse stallions between 4 and 20 yr of age were used 
during June and July.  They were housed in individual outdoor lots and were fed a 
commercially available, nutritionally balanced, pelleted ration plus free-choice grass hay 
to maintain body condition scores between 5 and 7 (Henneke et al., 1983). 
The day of treatment was d 0.  On that day, stallions were allotted to two groups 
such that age and breed type were evenly distributed in the groups.  One group was then 
randomly selected to receive a single deslorelin implant (n = 5) and the other group a 
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sham injection (n = 4).  All treatments were administered s.c. in the side of the neck.  
Samples of jugular blood were collected daily each morning from 5 d before through 13 d 
after injection.  On d 0, additional blood samples were collected at 0, 4, 8, and 12 h 
relative to treatment.  All blood samples were collected via jugular venipuncture into 
heparinized tubes and the plasma was harvested via centrifugation at 1,200 x g and stored 
at -15°C. 
 Experiment 2.  Twelve light horse geldings between 6 and 16 yr of age were used 
during May and June.  They were maintained as a group on native grass pasture and had 
body condition scores of 6 to 8 (Henneke et al., 1983). 
 All geldings were treated with estradiol and progesterone to mimic the normal 
changes in these steroid hormones during the estrous cycle (Ginther, 1992).  Starting on d 
-20, all geldings received daily i.m. injections of progesterone (500 µg/kg BW; Sigma) in 
corn oil to mimic the diestrous period; these injections were given in the morning for a 
total of 17 d (through d -4).  No injections were given on d -3.  On d -2, -1, and 0, all 
geldings received twice daily i. m. injections (morning and evening) of estradiol (17.5 
µg/kg BW; Sigma) to mimic the estrous period.  On the morning of d 0, the geldings 
were randomly allotted to groups and administered either a single deslorelin implant (n = 
6) or a sham injection (n = 6) s.c. in the neck.  Daily (morning) injections of progesterone 
were again given on d 2 (125 µg/kg), 3 (250 µg/kg), and 4 through 15 (500 µg/kg).  
Samples of jugular blood were collected immediately before any injections every day 
from d -20 through d 15; additional blood samples were collected at 0, 4, 8, and 12 h 
relative to deslorelin or sham injections on d 0. 
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 Sample and Statistical Analyses.  All plasma samples in both experiments were 
analyzed for LH and FSH via radioimmunoassay previously validated for horse samples 
(Thompson et al., 1983a,c).  Plasma samples from stallions in Exp. 1 were analyzed for 
testosterone using commercially available radioimmunoassay kit reagents (Diagnostic 
Systems Laboratory).  Intra- and interassay coefficients of variation and assay 
sensitivities were 6%, 9%, and 0.2 ng/mL for LH; 7%, 11%, and 1.4 ng/mL for FSH; and 
5%, 8%, and 0.02 ng/mL for testosterone. 
 Data were analyzed in each experiment via the GLM procedure of SAS (SAS Inst. 
Inc.).  Data from repetitive sampling over time (daily samples) were analyzed in a split-
plot ANOVA (Gill and Hafs, 1971) for a completely randomized design (Steel and 
Torrie, 1980).  The main effect of treatment was tested with the horse within treatment 
term; the main effect of time and its interaction with treatment were tested with the 
residual error term.  Differences between groups for each time period in the treatment x 
time interactions were assessed by the LSD-test (Steel and Torrie, 1980). 
 In Exp. 1, there was a large variation in gonadotropin concentrations among 
stallions before the onset of treatment, and in addition, their responses to treatment were 
multiplicative, not additive (varied proportionally with their pretreatment levels).  To 
account for this, the first five data points were averaged for each stallion, and then all his 
subsequent data points (d 0 through 13) were expressed as a percentage of that mean 
(Steel and Torrie, 1980).  Subsequent ANOVA as described above were performed on 
these data to determine treatment differences.  In Exp. 2, gonadotropin concentrations for 
the two treatment groups differed (P < 0.05) during the first progesterone treatment phase 
(d -20 through -4), when all geldings were treated the same.  To adjust for the 
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pretreatment differences between groups, the first 6 d of data were averaged for each 
gelding and subtracted from each of his subsequent data points; the resulting residuals 
were analyzed as described above to determine treatment differences (Steel and Torrie, 
1980). 
Results 
 Experiment 1.  Plasma concentrations of both LH and FSH (Figure 5.1a,b), 
expressed as percent of pretreatment, were elevated (P < 0.05) in the treated stallions at 4, 
8, and 12 h after deslorelin implant administration; in addition, plasma LH concentrations 
remained elevated (P < 0.05) at 24 h.  After that, LH concentrations decreased (P < 0.05) 
to below control concentrations by d 3 and remained low though d 13.  Plasma FSH 
concentrations in the treated stallions fell below (P < 0.05) control stallions on d 6 
through 13.  Plasma testosterone concentrations (Figure 5.1c) in the treated stallions 
followed a similar pattern to the gonadotropins in response to deslorelin implant 
administration, being elevated (P < 0.05) above controls at 4, 8, 12, 24, and 48 h.  In 
contrast to the gonadotropins, testosterone concentrations only fell below (P < 0.05) 
control concentrations on d 11 and 13. 
 Experiment 2.  On d -2, when all geldings began receiving estradiol injections, 
plasma LH concentrations (Figure 5.2a) began to increase.  Above that increase, plasma 
LH concentrations in treated geldings increased (P < 0.05) rapidly above control 
concentrations at 4, 8, and 12 h after administration of the deslorelin-containing implant.  
Thereafter, plasma LH concentrations decreased and were below (P < 0.05) control 
concentrations on d 2 through 7, d 9, and d 11 through 15.  During the mimicked diestrus  
-1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days relative to treatment
0
50
100
150
200
250
300
350
400
450
LH
, %
Control Deslorelin
***** *
**
*
*
** * * *
a
-1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days relative to treatment
0
50
100
150
200
250
300
FS
H
, %
*** * * *
*
*
**
*
b
-1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days relative to treatment
0
50
100
150
200
250
300
Te
st
os
te
ro
ne
, %
*
*
*
**
*
*
c
Figure 5.1 Plasma concentrations of LH (a), FSH (b), and testosterone (c) in deslorelin-treated and 
control stallions relative to the d of treatment (d 0).  Data are expressed as a percentage of 
pretreatment values.  Asterisks indicate differences (P < 0.05) between groups on specific days.  
The pooled SEM from the analyses of variance were 15.4, 9.9, and 20.6 percent for LH, FSH, and 
testosterone, respectively.
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Figure 5.2 Plasma concentrations of LH (a) and FSH (b) in deslorelin-treated and control geldings 
relative to the d of treatment (d 0).  Data are expressed as residuals due to pretreatment differences.  
Asterisks indicate differences (P < 0.05) between groups on specific days.  The pooled SEM from 
the analyses of variance were 0.63 and 2.28 ng/ml for LH and FSH, respectively.
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(d 2 through 15), when all geldings again received progesterone, plasma LH 
concentrations decreased in control geldings back to pre-estradiol concentrations.   
Within 1 d after the geldings began receiving estradiol, plasma FSH 
concentrations (Figure 5.2b) began to decrease in both groups.  Plasma FSH 
concentrations of treated geldings increased (P < 0.05) briefly on d 0 (4, 8, and 12 h) in 
response to the deslorelin implant, but began to decrease again by d 2 and were lower (P 
< 0.05) than control concentrations on d 4 through 12.  Plasma FSH concentrations in 
control geldings rebounded after the switch from estradiol injections to progesterone 
injections. 
 Discussion 
 Administration of a deslorelin implant resulted in an initial short-term increase in 
the gonadotropin concentrations in the treated stallions just as seen in mares following 
administration of a deslorelin implant (Donadeu, 1997).  This initial stimulation of LH 
and FSH secretion is coincident with the release of deslorelin from the implant (Donadeu, 
1997).  Deslorelin release from the implant reaches peak concentrations (approximately 
400 pg/mL) at 3 to 6 h after implantation and declines to near baseline within 24 h.  
Concentrations of LH and FSH follow a similar pattern to deslorelin, reaching peak 
concentrations 6 to 8 h after implantation and reaching baseline by 24 to 48 h.  After the 
initial increase, LH concentrations declined below controls for 11 d and were still 
suppressed when sampling was stopped.  FSH concentrations did not decline as rapidly as 
LH; however, by d 6 the FSH concentrations of the treated stallions were below controls. 
Concentrations of FSH in the treated stallions were still below controls on d 13 when 
blood sampling was stopped.  Testosterone concentrations followed the same initial 
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response as the gonadotropins following implant administration; however, there was no 
suppression of testosterone concentrations until the end of the sample period.  It is 
unclear whether testosterone concentrations remained suppressed due to sampling having 
stopped after 13 d.  If testosterone concentrations continued to be low, potential effects 
on libido and sperm production could occur, which may deserve further study. 
 The steroid treatment resulted in gonadotropin patterns similar to those seen 
during the estrous cycle in mares.  The pretreatment with progesterone allowed both 
gonadotropins to stabilize.  Estradiol treatment resulted in increasing LH concentrations 
in both groups prior to treatment with the deslorelin implant as well as decreasing FSH 
concentrations in both groups.  Once progesterone treatment resumed LH, concentrations 
declined in the controls while FSH concentrations increased.  This model of steroid 
treatment appears successful in mimicking the gonadotropin changes seen in mares 
during an estrous cycle.  The GnRH analogue implant was inserted on the morning of d 0, 
LH and FSH concentrations both increased in response to the deslorelin implant.  After 
the initial increase, concentrations of both gonadotropins began to rapidly decline.  The 
suppression of the gonadotropins is very similar to that reported in mares following 
treatment with the commercially available deslorelin implant, Ovuplant (Johnson et al., 
2000, 2002).  The suppression of the gonadotropins in the mares was from d 0 to 11 
relative to ovulation, whereas the geldings' gonadotropins were still suppressed 15 d after 
the implant was administered. 
 In conclusion, after an initial short-term stimulation of LH and FSH secretion, 
deslorelin implantation caused a long-term suppression of both gonadotropins in stallions 
as well as in steroid-treated geldings.  The suppression was very similar to that observed 
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in deslorelin-treated mares (Johnson et al., 2000, 2002).  Because blood sampling was 
stopped after d 13 for the stallions and d 15 for the steroid-treated geldings, it is not clear 
exactly how long the suppression of LH and FSH may have persisted.  Due to their 
responses, either of these male models may prove useful for studying this suppression of 
pituitary function in horses administered a slow-releasing deslorelin implant. 
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CHAPTER VI 
EFFECTS OF MULTIPLE GNRH ANALOG (DESLORELIN ACETATE)  
IMPLANTS ON CYCLIC MARES 
 
Introduction 
 Treatment with a commercially available GnRH analog (deslorelin acetate) 
implant (Ovuplant) results in a long-term (11 d) suppression of gonadotropin 
concentrations in mares (Johnson et al., 2000, 2002).  Those mares treated with the 
deslorelin implant to hasten ovulation had a prolonged interovulatory interval (>4 d; 
Johnson et al., 2000, 2002), most likely due to the gonadotropin suppression.  The 
gonadotropin suppression following treatment with a deslorelin implant was also 
observed in stallions and steroid-treated geldings (Chapter V).  Although this resulting 
gonadotropin suppression is an important concern, the bigger problem is the small 
percentage of mares that exhibit complete ovarian shutdown following treatment 
(Johnson et al., 2000).  This ovarian shutdown can last for weeks or months, resulting in 
mares being not breedable for the entire breeding season.  During this ovarian shutdown, 
gonadotropin levels rebound and reach castrate-like levels (Johnson et al., 2000) even 
though the ovary remains quiescent. 
Because only a small percentage of mares exhibit ovarian shutdown in response to 
Ovuplant, it has been hypothesized that such mares are more sensitive to the effects of 
deslorelin than the average mare.  If this is true, then multiple implants may induce 
ovarian shutdown in a greater percentage of mares.  A consistent means of producing 
ovarian shutdown is needed to study the underlying mechanism(s) responsible for its 
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occurrence.  Thus, the present experiment was designed to determine whether multiple 
deslorelin implants would result in a higher portion of ovarian shutdown in mares. 
Materials and Methods 
Twenty-one light horse mares with body condition scores of 5 to 7 (Henneke et 
al., 1983) were used beginning in April.  Mares were maintained on native grass pastures.  
All mares were determined to be though the transition period by progesterone 
concentrations >1 ng/mL for at least 12 d.  Mares were teased daily with a vigorous 
stallion for signs of behavioral estrus.  Ultrasound examinations were performed three 
times weekly for determination of follicular activity.  Ultrasound exams were performed 
daily once a mare developed a follicle >25 mm in diameter or once she exhibited 
behavioral signs of estrus.   
On the day a mare developed a follicle >30 mm, she was randomly assigned to 
one of three treatments:  1) 3 deslorelin implants administered s. c. in 1 d, 2) 1 deslorelin 
implant consecutively for 3 d, or 3) a single sham injection (control).  Treatment 
assignments and administration were performed by personnel other than those performing 
the data collection and were unknown to those involved in data collection.  Follicular 
activity was assessed on a daily basis from the first treatment through two ovulations or 
for 30 d.  If a mare had not ovulated for the second time by d 30 relative to the first 
ovulation, ultrasound exams were performed twice weekly until she ovulated or until 90 d 
after the first ovulation. 
Blood samples were collected via jugular venipuncture into heparinized tubes on 
a daily basis beginning when a follicle >25 mm was detected or when the mare showed 
behavioral signs of estrus; this sampling was continued until 4 d after the second 
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ovulation or 30 d after the first ovulation.  If the mare had not ovulated by 30 d following 
the first ovulation, blood samples were collected twice weekly until the second ovulation 
or for 90 d from the first ovulation. 
Additional samples of blood were collected at 0, 2, 4, 8, 12, 24, 26, 28, 32, 36, 48, 
50, 52, 56, and 60 h relative to the first treatment.  Plasma was harvested from all 
samples via centrifugation at 1,200 x g and stored at -15° C until assayed.  All daily 
samples were analyzed for LH and FSH in radioimmunoassays previously validated for 
horses tissues (Thompson et al., 1983a,c).  Progesterone was measured in daily samples 
using commercially available reagents (Diagnostic Systems Laboratory). 
Data were analyzed via the GLM procedure of SAS (SAS Institute Inc.).  Data 
from repetitive sampling over time (daily and hourly samples) were analyzed in a split-
plot ANOVA (Gill and Hafs, 1971) for a completely randomized design (Steel and 
Torrie, 1980).  Differences among treatment groups in the treatment x time interaction(s) 
were assessed by the LSD-test (Steel and Torrie, 1980). 
Results 
 The interovulatory interval was extended (P = 0.0004) in both deslorelin-treated 
groups relative to control mares (36.8 vs 22.0 d, SEM = 2.1; Table 6.1), but the two 
treated groups did not differ from each other.  The diameter of the largest follicle (Table 
6.1) did not differ on the day of treatment, the day prior to ovulation (d -1), the day of 
ovulation (d 0), or on d 1 to 7 after the first ovulation.  The diameter of the largest follicle 
in both groups of mares receiving deslorelin (Figure 6.1) was smaller (P < 0.05) than in 
control mares on d 8, 9, 11, and d 13 through 23 after the first ovulation.  Mares receiving  
Figure 6.1 Diameter of the largest follicle for mares administered sham injections (control), 
treated with 3 deslorelin implants in 1 d (deslorelin3-1), or treated with 1 deslorelin implant 
per day for 3 consecutive days (deslorelin1-3) during the first estrus.  Data are expressed 
relative to the day of ovulation on the first estrus (d 0) for all groups.  The vertical line 
indicates the P < 0.05 value.
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Table 6.1.  Intervals from treatment to ovulation, between first and second ovulation, and 
diameter of the largest follicle. 
 
Item Control Deslorelin3-1a Deslorelin1-3b SEM P-value 
Treatment to 
ovulation, d 
3.9 3.3 2.1 0.79 0.32 
Interovulatory interval, 
d 
22.5 36.8 36.9 2.06 0.0004 
First estrus length, d 6.33 7.14 4.71 1.08 0.297 
Second estrus length, d 5.75 12.6 14.1 2.73 0.205 
Return to estrus, d 16.0 27.0 23.0 2.57 0.089 
Largest follicle on day 
of treatment, mm 
32.4 32.7 34.1 0.60 0.128 
 a Three implants administered in 1 d. 
 b One implant administered daily for 3 d. 
3 implants at treatment also had a reduced (P < 0.05) largest follicle than control mares 
on d 10 and 12.  Diameter of the largest follicle was similar (P >0.05) for the two treated 
groups throughout the experiment.  There was no difference (P > 0.05) among groups in 
the length of estrus for the first or second ovulation (Table 6.1). 
Relative to treatment, LH concentrations (Figure 6.2a) in mares receiving 3 
implants at treatment were higher (P < 0.05) at 8 and 12 h following implantation than in 
control mares or in mares receiving one implant daily for 3 d.  Concentrations of LH for 
both deslorelin treated groups were suppressed (P < 0.05) below control values on d 4, 5, 
and 6 relative to the day of treatment.  Daily FSH concentrations for mares receiving 3 
implants at treatment (Figure 6.2b) were elevated (P < 0.05) above controls at 4, 8, 12, 
24, 26, 28, 32, and 36 h after implantation.  Mares receiving three implants at treatment 
had higher (P < 0.05) FSH concentrations at 8 h following treatment than mares receiving 
one implant daily for 3 d.  Concentrations of FSH for mares receiving 1 implant daily for 
3 d were higher (P < 0.05) at 2, 4, 8, 12, 26, 32, and 36 h following treatment than those 
of control mares.  Concentrations of FSH in mares receiving 3 implants at treatment were  
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Figure 6.2 Plasma concentrations of LH (a) and FSH (b) in mares administered sham injections 
(control), treated with 3 deslorelin implants in 1 d (deslorelin3-1), or treated with 1 deslorelin 
implant per day for 3 consecutive days (deslorelin1-3) during the first estrus.  Data are expressed 
relative to the day of treatment on the first estrus (d 0) for all groups.  The vertical line indicates 
the P < 0.05 value.  The pooled SEM from the analyses of variance were 2.42 and 2.76 ng/ml for 
LH and FSH, respectively.
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suppressed (P < 0.05) below controls on d 6, while FSH concentrations in mares 
receiving one implant daily for 3 d were suppressed (P < 0.05) below controls on d 5 and 
6. 
Daily LH concentrations (Figure 6.3a) were lower (P < 0.05) in both deslorelin-
treated groups than in controls on d -2, d 0 to 6, and d 18 to 25.  Concentrations of LH in 
mares receiving one implant daily for 3 d were also lower (P < 0.05) than in controls on d 
-1.  Daily plasma LH concentrations in the two deslorelin treated groups did not differ (P 
> 0.05) from one another throughout the study.  Concentrations of FSH (Figure 6.3b) in 
the two treated groups were suppressed (P < 0.05) below control values on d 3, 5, 6, 7, 9 
through 14, 17, 18, 19, and 20.  Plasma FSH concentrations in mares receiving three 
implants at treatment were also lower (P < 0.05) than in controls on d 4, 8, 15, and 16.  
Daily plasma FSH concentrations in the two deslorelin-treated groups did not differ (P > 
0.05) from each other throughout the study. 
Concentrations of progesterone (Figure 6.4) were higher (P < 0.05) in the mares 
receiving 1 implant per day for 3 consecutive days than in controls on d 11, 12, and 13, 
and were higher (P < 0.05) than in the mares receiving 3 implants on the day of treatment 
on d 13.  With the exception of d 11 to 13, progesterone concentrations were similar 
between all groups throughout the study.  No mares exhibited complete ovarian shutdown 
as had been reported in the previous research. 
Discussion 
 As in previous experiments (Johnson et al., 2000, 2002;  Morehead et al., 2000 
and Vanderwall et al., 2001), administration of the commercially available GnRH 
agonist, Ovuplant, to estrous mares resulted in an extension of the interovulatory interval 
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Figure 6.3 Plasma concentrations of LH (a) and FSH (b) in mares administered sham injections 
(control), treated with 3 deslorelin implants in 1 d (deslorelin3-1), or treated with 1 deslorelin 
implant per day for 3 consecutive days (deslorelin1-3) during the first estrus.  Data are expressed 
relative to the day of ovulation on the first estrus (d 0) for all groups.  The vertical line indicates 
the P < 0.05 value.  The pooled SEM from the analyses of variance were 1.70 and 2.37 ng/ml for 
LH and FSH, respectively.
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Figure 6.4 Plasma concentrations of progesterone in mares administered sham injections 
(control), treated with 3 deslorelin implants in 1 d (deslorelin3-1), or treated with 1 deslorelin 
implant per day for 3 consecutive days (deslorelin1-3) during the first estrus.  Data are 
expressed relative to the day of ovulation on the first estrus (d 0) for all groups.  The vertical 
line indicates the P < 0.05 value.  The pooled SEM from the analysis of variance was 1.99 
ng/ml for progesterone.
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and a suppression of follicular activity and gonadotropin concentrations.  In previous 
experiments (Johnson et al., 2000, 2002), a single deslorelin implant caused a consistent 
suppression in daily concentrations of both LH and FSH for 10 to 14 d.  The suppression 
of the gonadotropins in the deslorelin-treated mares is likely the cause of the prolonged 
interovulatory interval seen in those mares (Johnson et al., 2000, 2002).  The 
interovulatory interval for mares receiving a total of three deslorelin implants (36.8 d) 
was considerably longer than observed in mares receiving only one implant (25.4 d; 
Chapter IV).  This agrees with the longer suppression of the gonadotropins (~20 to 25 d) 
seen in mares receiving 3 implants. 
 The reduced diameter of the largest follicle in the deslorelin-treated mares on d 8 
though 23 is further evidence of the suppression of the gonadotropins, although the 
diameter of the largest follicle did not differ on d 24 or 25.  This latter fact is due to the 
control mares already having ovulated the dominant follicle of the second estrus.  The 
diameter of the largest follicle for the treated groups were similar throughout the study 
indicating that there is no difference in treating mares with three deslorelin implants at 
once or one deslorelin implant per day for three consecutive days.    
 Although treatment with a total of three deslorelin implants resulted in a longer 
suppression of follicular activity and gonadotropin secretion, it did not induce a long-
term ovarian shutdown as seen in one mare previously (Johnson et al., 2000).  That mare, 
which experienced total ovarian shutdown for the entire breeding season, was followed 
through the next breeding season.  After an apparently normal ovulation, treatment with a 
single Ovuplant again resulted in complete ovarian shutdown for the second season.  
Thus, the question arises as to why certain mares exhibit complete ovarian shutdown in 
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response to a single deslorelin implant whereas the average, or typical, mare does not 
necessarily shut down after three implants.  It is possible that the percentage of mares that 
are exceptionally sensitive to deslorelin is extremely small and by chance none were in 
the treatment groups in this experiment.  This is reassuring for the breeder, because the 
chance of having a mare shut down in response to a deslorelin implant is minimal.  
However, some means of detecting the sensitive mares prior to treatment with deslorelin 
would be beneficial to avoid treating those mares. 
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CHAPTER VII 
 
SUMMARY AND CONCLUSIONS 
 
 Mares treated with Ovuplant to hasten ovulation experience a prolonged 
interovulatory interval following the induced ovulation.  This agrees with the field reports 
that began to circulate soon after the horse industry started using Ovuplant.  Mares 
treated with the deslorelin containing implants had an extended interovulatory interval 
whether short-cycled with PGF2α or allowed to cycle normally.  The extended 
interovulatory interval reported in deslorelin-treated mares was accompanied by a 
decrease in follicular activity.  Concentrations of LH and FSH were suppressed during 
the estrous cycle following deslorelin treatment.  This suppression of gonadotropins is 
likely the reason for the diminished follicular activity as well as the lengthening of the 
interovulatory interval.  The deslorelin-induced suppression of the gonadotropins is 
consistent in stallions and steroid-treated geldings. 
 Following treatment with deslorelin, mares experience a lack of pituitary 
responsiveness to exogenous GnRH stimulation.  The insensitivity to exogenous GnRH 
and the suppression of the gonadotropins are indicative of the down-regulation seen in 
other species following treatment with GnRH or its analogs.  Although the horse has been 
thought to be relatively resistant to down-regulation, it would appear that this analog, 
delivered in a slow-release implant, is capable of causing a short-lived (~10 to 14 d) 
down-regulation in the horse.  
 Treatment with multiple deslorelin implants on the same day or over three 
consecutive days results in a longer extension of the interovulatory interval.  In spite of 
this, no mares exhibited the complete ovarian shutdown seen in one mare from the first 
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experiment.  Therefore, the reason that some mares experience ovarian shutdown, 
characterized by anestrous-like ovaries under castrate-level gonadotropins, remains 
unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62
REFERENCES 
 
Alexander, S. L., and C. H. G. Irvine. 1986. Effect of graded doses of gonadotrophin-
releasing hormone on serum LH concentrations in mares in various reproductive 
states: Comparison with endogenously generated LH pulses. J. Endocrinol. 
110:19-26. 
 
Alexander, S. L., and C. H. G. Irvine. 1987. Secretion rates and short-term patterns of 
gonadotrophin-releasing hormone, FSH and LH throughout the periovulatory 
period in the mare. J. Endocrinol. 114:351-362. 
 
Alexander, S. L., and C. H. G. Irvine. 1993. FSH and LH. Pages 45-56 in Equine 
Reproduction. A. O. McKinnon and J. L. Voss, eds. Lea & Fibiger, Philadelphia, 
PA. 
 
Allen, W. R., M. W. Sanderson, R. E. S. Greenwood, D. R. Ellis, J. S. Crowhurst, D. J. 
Simpson, and P. D. Rossdale. 1987. Induction of ovulation in anoestrous mares 
with a slow-release implant of a GnRH analogue (ICI 118 630). J. Reprod. Fertil. 
35 (Suppl.):469-478. 
 
Bailey, V. E., and R. H. Douglas. 1977. Induction of ovulation in seasonally-anovulatory 
mares with GnRH. Page 336 in Proc. Am. Soc. Anim. Sci., Madison, WI.  
(Abstr.) 
 
Belchetz, P. E., T. M. Plant, Y. Nakai, E. J. Keogh, and E. Knobil. 1978. Hypophysial 
responses to continuous and intermittent delivery of hypothalamic 
gonadotropin-releasing hormone. Science 202:631-633. 
 
Clayton, R. N. 1989. Gonadotrophin-releasing hormone:  Its actions and receptors. J. 
Endocrinol. 120:11-19. 
 
Conn, P. M., D. Staley, C. Harris, W. V. Andrews, W. C. Gorospe, C. A. McArdle, W. R. 
Huckle, and J. Hansen. 1986. Mechanism of action of gonadotropin releasing 
hormone. Annu. Rev. Physiol. 48:495-513. 
 
Conn, P. M., W. R. Huckle, W. V. Andrews, and C. A. McArdle. 1987. The molecular 
mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary.  
Recent Prog. Horm. Res. 43:29-68. 
 
Crowder, M. E., R. D. Herring, and T. M. Nett. 1986. Rapid recovery of gonadotroph 
function after down-regulation of receptors for GnRH in ewes. J. Reprod. Fertil. 
78:577-585. 
 
Donadeu, F. F. X. 1997. Evaluation of deslorelin during the breeding season and of 
sulpiride during seasonal anestrus for induction of ovulation in mares. M.S. 
Thesis, Louisiana State Univ., Baton Rouge.  
 63
Dyer, R. G., and J. E. Robinson. 1989. The LHRH pulse generator. J. Endocrinol. 123:1-
2. 
 
Evans, M. J., and C. H. G. Irvine. 1976. Measurement of equine FSH and LH: Response 
of anestrous mares to gonadotropin-releasing hormone. Biol. Reprod.15:477-484. 
 
Evans, M. J., and C. H. G. Irvine. 1977. Induction of follicular development, maturation 
and ovulation by gonadotropin releasing hormone administration to acyclic mares.  
Biol. Reprod. 16:452-456. 
 
Evans, M. J., and C. H. G. Irvine. 1979. Induction of follicular development and 
ovulation in seasonally acyclic mares using gonadotrophin-releasing hormones 
and progesterone. J. Reprod. Fertil. Suppl. 27:113-121. 
 
Farquhar, V. J., P. M. McCue, T. M. Nett, and E. L. Squires. 2001. Effect of deslorelin 
acetate on gonadotropin secretion and ovarian follicle development in cycling 
mares. J. Am. Vet. Med. Assoc. 218:749-752. 
 
Fitzgerald, B. P., K. D. Peterson, and P. J. Silvia. 1993. Effect of constant administration 
of a gonadotropin-releasing hormone agonist on reproductive activity in mares: 
Preliminary evidence on suppression of ovulation during the breeding season. 
Am. J. Vet. Res. 54:1746-1751. 
 
Fitzgerald, B. P., A. F. Micka, and S. L. Meyer. 1990. Suppression of circulating 
concentrations of lutenising hormone (LH) in ovariectomised (OVX) mares by 
constant administration of an agonist analogue (wy-40972) of gonadotrophin-
releasing hormone (GnRH). Pages 106-107 in Proc. Internatl. Symp. Equine 
Reprod., Deauville, France. (Abstr.) 
 
Fraser, H. M. 1981. Luteinizing hormone-releasing hormone and fertility control. Oxford 
Rev. Reprod. Biol. 3:1-48. 
 
Garcia, M. C., and O. J. Ginther. 1975. Plasma luteinizing hormone concentration in 
mares treated with gonadotropin-releasing hormone and estradiol.  Am. J. Vet. 
Res. 36:1581-1584. 
 
Garcia, M. C., and O. J. Ginther. 1978. Regulation of plasma LH by estradiol and 
progesterone in ovariectomized mares. Biol. Reprod. 19:447-453. 
 
Garza, F., Jr., D. L. Thompson, Jr., D. D. French, J. J. Wiest, R. L. St. George, K. B. 
Ashley, L. S. Jones, P. S. Mitchell, and D. R. McNeill. 1986. Active 
immunization of intact mares against gonadotropin releasing hormone:  
Differential effects on secretion of luteinizing hormone and follicle-stimulating 
hormone. Biol. Reprod. 35:347-352. 
 
 64
Gánheim, A., A. Gánheim, and W. Jöchle. 1995. Acceleration and timing of fertile 
ovulation in cyclic mares with a deslorelin implant. Acta. Vet. Scand. 36:393-400. 
 
Gill, J. L., and H. D. Hafs. 1971. Analysis of repeated measurements of animals. J. Anim. 
Sci. 33:331-336. 
 
Ginther, O. J. 1992. Reproductive Biology of the Mare: Basic and Applied Aspects. 
Equiservices, Cross Plains, WI. 
 
Ginther, O. J., and B. C. Wentworth. 1974. Effect of a synthetic gonadotropin-releasing 
hormone on plasma concentrations of luteinizing hormone in ponies. Am. J. Vet. 
Res. 35:79-81. 
 
Guyton, A. C., and J. E. Hall. 1996. Textbook of Medical Physiology. 9th ed. W. B. 
Saunders Co., Philadelphia, PA. 
 
Hart, P. J., E. L. Squires, K. J. Imel, and T. M. Nett. 1984. Seasonal variation in 
hypothalamic content of gonadotropin-releasing hormone (GnRH), pituitary 
receptors for GnRH, and pituitary content of lutenizing hormone and follicle-
stimulating hormone in the mare. Biol. Reprod. 30:1055-1062. 
 
Heber, D., and R. S. Swerdloff. 1981. Down-regulation of pituitary gonadotropin 
secretion in postmenopausal females by continuous gonadotropin-releasing 
hormone administration. J. Clin. Endocrinol. & Metab. 52:171-172. 
 
Heinze, H., and E. Klug. 1975. The use of Gn-RH for controlling the oestrous cycle of 
the mare (preliminary report). J. Reprod. Fertil. Suppl. 23:275-277. 
 
Henneke, D. R., G. D. Potter, J. L. Kreider, and B. F. Yeates. 1983. Relationship between 
condition score, physical measurements and body fat percentage in mares. Equine 
Vet. J. 15:371-376. 
 
Hyland, J. H., P. J. Wright, I. J. Clarke, R. S. Carson, D. A. Langsford, and L. B. Jeffcoat. 
1987. Infusion or gonadotrophin-releasing hormone (GnRH) induces ovulation 
and fertile oestrus in mares during seasonal anoestrus. J. Reprod. Fertil. Suppl. 
35:211-220. 
 
Irvine, C. H. G., and S. L. Alexander. 1993. GnRH. Pages 37-44 in Equine Reproduction. 
A. O. McKinnon and J. L. Voss, eds. Lea & Fibiger, Philadelphia, PA. 
 
Irvine, C. H. G. 1983. Gonadotropin-releasing hormone. J. Equine Vet. Sci. 3:168-170. 
 
Irvine, D. S., B. R. Downey, W. G. Parker, and J. J. Sullivan. 1975. Duration of oestrus 
and time of ovulation in mares treated with synthetic Gn-RH (AY-24,031).  J. 
Reprod. Fertil. Suppl. 23:279-283. 
 
 65
Jöchle, W., and T. E. Trigg. 1994. Control of ovulation in the mare with Ovuplant, a 
short-term release implant (STI) containing the GnRH analogue deslorelin 
acetate: Studies from 1990 to 1994. (A review). J. Equine Vet. Sci. 14:632-644. 
 
Johnson, C. A., D. L. Thompson, Jr., and J. A. Cartmill. 2001. Effects of Ovuplant™ on 
LH and FSH secretion in stallions and steroid-treated geldings.  Pages 464-465 in 
Proc. 17th Equine Nutr. Physiol. Symp. Lexington, KY. 
 
Johnson, C. A., D. L. Thompson, Jr., K. M. Kulinski, and A. M. Guitreau. 2000. 
Prolonged interovulatory interval and hormonal changes in mares following the 
use of Ovuplant™ to hasten ovulation. J. Equine Vet. Sci. 20:331-336. 
 
Johnson, C. A., D. L. Thompson, Jr., and J. A. Cartmill. 2002. Pituitary responsiveness to 
GnRH in mares following deslorelin acetate implantation to hasten ovulation. J. 
Anim. Sci. 80:(In press). 
 
Knobil, E. 1980. The neuroendocrine control of the menstral cycle. Recent Prog. Horm. 
Res. 36:53-88. 
 
Lubbecke, M., E, Klug, H. O. Hoppen, and W. Jöchle. 1994. Attempts to synchronize 
estrus and ovulation in mares using progesterone (CIDR-B) and GnRH-analog 
deslorelin. Reprod. Domest. Anim. 29:305-314. 
 
Loy, R. G., and J. P. Hughes. 1966. The effects of human chorionic gonadotrophin on 
ovulation, length of estrus and fertility in the mare. Cornell Vet. 56:41-50. 
 
McKinnon, A. O., A. M. Nobellius, S. Tarrida del Marmol Figueroa, J. Skidmore, J. R. 
Vasey, and T. E. Trigg. 1993. Predictable ovulation in mares treated with an 
implant of the GnRH analogue deslorelin. Equine Vet. J. 25:321-323. 
 
McKinnon, A. O., J. R. Vasey, T. B. Lescun, and T. E. Trigg. 1997. Repeated use of a 
GnRH analogue deslorelin (Ovuplant) for hastening ovulation in the transitional 
mare. Equine Vet. J. 29:153-155. 
 
Meinert, C., J. F. Silva, I. Kroetz, E. Klug, T. E. Trigg, H. O. Hoppen, and W. Jöchle. 
1993. Advancing the time of ovulation in the mare with a short-term implant 
releasing the GnRH analogue deslorelin. Equine Vet. J. 25:65-68. 
 
Monahan, M. W., M. S. Amoss, H. A. Anderson, and W. Vale. 1973. Synthetic analogs 
of the hypothalamic luteinizing hormone-releasing factor with increased agonist 
of antagonist properties. Biochemistry 12:4616-4620. 
 
Montovan, S. M., P. P. Daels, J. Revier, J. P. Hughes, G. H. Stabenfeldt, and B. L. 
Lasley. 1990. The effect of a potent GnRH agonist on gonadal and sexual activity 
in the horse. Theriogenology 33:1305-1321. 
 
 66
Morehead, J. A., and T. L. Blanchard. 2000. Clinical experience with deslorelin 
(Ovuplant) in a Kentucky Thoroughbred broodmare practice (1999). J. Equine 
Vet. Sci. 20:358-402. 
 
Mumford, E. L., E. L. Squires, W. Jöchle, L. A. Harrison, T. M. Nett, and T. E. Trigg. 
1995. Use of deslorelin short-term implants to induce ovulation in cycling mares 
during three consecutive estrous cycles. Anim. Reprod. Sci. 39:129-140. 
 
Meyers, P. J., T. Bowman, G. Blodgett, H. S. Conboy, T. Gimenez, M. P. Reid, B. C. 
Taylor, J. Thayer, W. Jöchle, and T. E. Trigg. 1997. Use of the GnRH analogue, 
deslorelin acetate, in a slow-release implant to accerlerate ovulation in oestrous 
mares. Vet. Rec. 140:249-252. 
 
Nett, T. M., M. E. Crowder, G. E. Moss, and T. M. Duello. 1981. GnRH-receptor 
interaction. V. Down-regulation of pituitary receptors for GnRH in 
ovariectomized ewes by infusion of homologous hormone. Biol. Reprod. 
24:1145-1155. 
 
Palmer, E., and P. Quellier. 1988. Uses of LHRH and analogues in the mare. Pages 339-
346 in Proc. 5th Internatl. Cong. Anim. Reprod. Artif. Insem., Dublin, Ireland. 
 
Reville-Moroz, S. I., D. L. Thompson, Jr., L. F. Archbald, and L. M. Olsen. 1984. Effects 
of in vivo administration of testosterone propionate on in vitro production of 
follicle-stimulating hormone and lutenizing hormone by pituitaries of pony mares.  
Biol. Reprod. 30:673-678. 
 
Roser, J. F., B. L. Kiefer, J. W. Evans, D. P. Nealy, and C. A. Pacheco. 1979. The 
development of antibodies to human chorionic gonadotrophin following its 
repeated injection in the cyclic mare. J. Reprod. Fertil. Suppl. 27:173-179. 
 
Sandow, J. 1983. The regulation of LHRH action at the pituitary and gonadal receptor 
level: A review. Psychoneuroendocrinology 8:277-297. 
 
Sandow, J. 1978. Structure-activity relationships in the LH-RH molecule. Pages 49-70 in 
Control of Ovulation.  D. B. Crighton, N. B. Haynes, N. B. Foxcroft, G. R. 
Lamming, and G. E. Lamming eds. Butterworth, London. 
 
Safir, J. M., R. G. Loy, and B. P. Fitzgerald. 1987. Inhibition of ovulation in the mare by 
active immunization against LHRH. J. Reprod. Fertil Suppl. 32:261-267. 
 
Savoy-Moore, F. T., and K. H. Swartz. 1987. Several GnRH stimulation frequencies 
differentially release FSH and LH from isolated, perfused rat anterior pituitary 
cells. Adv. Exp. Med. Biol. 219:641-645. 
 
 67
Sharp, D. C., and W. R. Grubaugh. 1987. Use of push-pull perfusion techniques in 
studies of gonadotrophin-releasing hormone secretion in mares. J. Reprod. Fertil. 
Suppl. 35:289-296. 
 
Silvia, P. J., E. L. Squires, and T. M. Nett. 1986. Changes in the hypothalamic-
hypophyseal axis of mares associated with seasonal reproductive recrudescence.  
Biol. Reprod. 35:897-905. 
 
Smith, M. A., M. H. Perrin, and W. W. Vale. 1983. Desensitization of cultured pituitary 
cells to gonadotropin-releasing hormone: evidence for post-receptor mechanism. 
Mol. Cell. Endocrinol. 30:85-96. 
 
Squires, E. L., R. A. Wallace, J. L. Voss, B. W. Pickett, and R. K. Shideler. 1981. The 
effectiveness of PGF2α, HCG, and GnRH for appointment breeding of mares. J. 
Equine Vet. Sci. 1:5-9. 
 
Squires, E.L., D. M. Moran, M. E. Farlin, D. J. Jasko, T. J. Keefe, S. A. Meyers, E. 
Figueiredo, P. M. McCue, and W. Jöchle. 1994. Effect of dose of GnRH analog 
on ovulation in mares. Theriogenology 41:757-769. 
 
Steel, R. G. D. and J. H. Torrie. 1980. Principles and Procedures of Statistics: A 
Biometrical Approach. 2nd ed. McGraw-Hill Book Co., New York. 
 
Strauss, S. S., C. L. Chen, S. P. Kalra, and D. C. Sharp. 1979. Localization of 
gonadotrophin-releasing hormone (GnRH) in the hypothalamus of ovariectomized 
pony mares by season. J. Reprod. Fertil Suppl. 27:123-129. 
 
Sullivan, J. J., W. G. Parker, and L. L. Larson. 1973. Duration of estrus and ovulation 
time in nonlactating mares given HCG during three successive estrous periods. J. 
Am. Vet. Med. Assoc. 163:895-898. 
Thompson, D. L., Jr, B. W. Pickett, E. L. Squires, and T. M. Nett. 1979. Effect of 
testosterone and estradiol-17ß alone and in combination on LH and FSH 
concentrations in pituitary and blood serum of geldings and in serum after GnRH.  
Biol Reprod 21:1231-1237. 
Thompson, D. L., Jr., R. A. Godke, and E. L. Squires. 1983a. Testosterone effects on 
mares during synchronization with altrenogest: FSH, LH, estrous detection and 
pregnancy rate. J. Anim. Sci. 56:678-686. 
Thompson, D. L., Jr., S. I. Reville, D. J. Derrick, and M. P. Walker. 1983b. Effects of 
testosterone, dihydrotestosterone and estradiol on gonadotropin release after 
gonadotropin releasing hormone administration in cyclic mares. Biol. Reprod. 
29:970-976. 
 68
Thompson, D. L., Jr., S. I. Reville, M. P. Walker, D. J. Derrick, and H. Papkoff. 1983c. 
Testosterone administration to mares during estrus: Duration of estrus and 
diestrous and concentrations of LH and FSH in plasma. J. Anim. Sci. 56:911-918. 
 
Thompson, D. L., Jr., F. Garza, R. L. St. George, M. H. Rabb, B. E. Barry, and D. D. 
French. 1991. Relationships among LH, FSH and prolactin secretion, storage and 
response to secretagogue and hypothalamic GnRH content in ovariectomized 
pony mares administered testosterone, dihydrotestosterone, estradiol, 
progesterone, dexamethasone or follicular fluid. Domest. Anim. Endocrinol. 
8:189-199. 
 
Turner, J. E., and C. H. G. Irvine. 1992. The effect of a potent GnRH agonist on gonadal 
and sexual activity in the horse. Theriogenology 33:213-225. 
 
Vanderwall, D. K., T. D. Juergens, and G. L. Woods. 2001. Reproductive performance of 
commercial broodmares after induction of ovulation with hCG or Ovuplant™ 
(deslorelin). J. Equine Vet. Sci. 21:539-542. 
 
Voss, J. L., J. J. Sullivan, B. W. Pickett, W. G. Parker, L. D. Burwash, and L. L. Larson.  
1975. The effect of HCG on duration of oestrus, ovulation time and fertility in 
mares. J. Reprod. Fertil. Suppl. 23:297-301. 
 
Zilberstein, M., H. Zakut, and Z. Naor. 1983. Coincidence of down-regulation and 
desensitization in pituitary gonadotrophs stimulated by gonadotropin releasing 
hormone. Life Sci. 32:663-669. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 69
APPENDIX:  LETTERS OF PERMISSION
70
71
72
 73
                                                      VITA 
 
 Carrie Ann Johnson was born on April 19, 1974, to Donnie Strebeck and Stella 
Dannheim in Crossett, Arkansas.  Carrie attended Crossett High School and received her 
academic diploma in May, 1992.  In the fall of 1992, Carrie attended Northeast Louisiana 
University in Monroe, Louisiana, on a rodeo scholarship and obtained her bachelor of 
science degree in agribusiness in May, 1996.  Carrie then began working on a master of 
science degree in biology under the direction of Dr. Ann Findley and Dr. William 
Hoefler.  She obtained her master of science degree in August, 1998.  In August, 1998, 
Carrie began her doctor of philosophy program in equine physiology and reproduction at 
Louisiana State University in Baton Rouge, Louisiana, under the direction of Dr. Donald 
L. Thompson, Jr.  Carrie completed her requirements for the doctor of philosophy degree 
in the summer of 2002. 
 
